Marzia Rossi

ORCID: 0000-0003-4336-8502
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis B Virus Studies
  • Immune Cell Function and Interaction
  • Hepatitis C virus research
  • Immunotherapy and Immune Responses
  • Advanced Radiotherapy Techniques
  • SARS-CoV-2 and COVID-19 Research
  • vaccines and immunoinformatics approaches
  • Medical Imaging Techniques and Applications
  • Viral gastroenteritis research and epidemiology
  • Lung Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Cytomegalovirus and herpesvirus research
  • Radiomics and Machine Learning in Medical Imaging
  • Liver Disease Diagnosis and Treatment
  • Family and Patient Care in Intensive Care Units
  • Maternal and fetal healthcare
  • COVID-19 and Mental Health
  • Immunodeficiency and Autoimmune Disorders
  • HIV Research and Treatment
  • Reproductive tract infections research
  • Cell death mechanisms and regulation
  • Ectopic Pregnancy Diagnosis and Management
  • Hepatitis Viruses Studies and Epidemiology
  • COVID-19 Clinical Research Studies
  • Ultrasound in Clinical Applications

University of Parma
2017-2024

Marconi University
2024

Ospedale di Parma
2015-2022

Ospedale “M. Bufalini” di Cesena
2021

The Netherlands Cancer Institute
2016

Istituto Giannina Gaslini
2011

Chelsea and Westminster Hospital NHS Foundation Trust
2009

European Institute of Oncology
2007-2008

Ripamonti
2008

University of Milan
2007

<h3>Objective:</h3> To determine the prevalence of rectal chlamydia infection in a cohort men who have sex with (MSM) and proportion that would be missed without routine screening. <h3>Methods:</h3> MSM presenting to four HIV/GUM outpatient clinics at Chelsea &amp; Westminster Hospital NHS Foundation Trust between 1 November 2005 29 September 2006 were offered testing for addition their screen sexually transmitted infections (STIs). <i>Chlamydia trachomatis</i> (CT) tests performed using...

10.1136/sti.2008.031773 article EN Sexually Transmitted Infections 2009-01-28

Natural killer (NK) and hepatitis B virus (HBV)‐specific T cells are functionally impaired in chronic (CHB). Understanding to what extent nucleos(t)ide analogue (NUC) therapy can improve T‐ NK‐cell responses is important the perspective of immunomonitoring strategies for a safe earlier NUC withdrawal novel combination therapies based on modulation antiviral immunity. To gain further insights into T/NK‐cell interplay, we studied phenotype function e antigen–negative HBV patients either...

10.1002/hep.28155 article EN Hepatology 2015-09-11

Abstract Hepatitis C virus infection (HCV) represents a unique model to characterize, from early late stages of infection, the T cell differentiation process leading exhaustion human CD8+ cells. Here we show that in HCV exhaustion-committed virus-specific cells display marked upregulation transcription associated with impaired glycolytic and mitochondrial functions, are linked enhanced ataxia-telangiectasia mutated (ATM) p53 signaling. After evolution chronic HCV-specific responses is...

10.1038/s41467-019-14137-7 article EN cc-by Nature Communications 2020-01-30

In chronic HBV infection, mitochondrial functions and proteostasis are dysregulated in exhausted HBV-specific CD8 T cells. To better characterise the potential involvement of deregulated protein degradation mechanisms cell exhaustion, we analysed lysosome-mediated autophagy Bioactive compounds able to simultaneously target both were tested identify optimal combination strategies reconstitute efficient antiviral responses patients with infection.Lysosome-mediated pathways by flow cytometry...

10.1016/j.jhep.2020.10.034 article EN cc-by-nc-nd Journal of Hepatology 2020-11-11

Exhausted hepatitis B virus (HBV)-specific CD8 T cells in chronic HBV infection are broadly heterogeneous. Characterisation of their functional impairment may allow to distinguish patients with different capacity control and reconstitute antiviral function.HBV dextramer+CD8 were analysed ex vivo for coexpression checkpoint/differentiation markers, transcription factors cytokines 35 HLA-A2+chronic (CHB) 29 HBsAg negative CHB who seroconverted after NUC treatment or spontaneously. Cytokine...

10.1136/gutjnl-2022-327202 article EN cc-by Gut 2023-01-30

RNA interference molecules have some advantages as cancer therapeutics, including a proved efficacy on both wild-type (WT) and mutated transcripts an extremely high sequence-specificity. The most significant hurdle to be overcome if exogenous small interfering RNAs (siRNA) is used therapeutically the specific, effective, nontoxic delivery of siRNA its intracellular site action. At present, human applications are confined almost exclusively targets within liver, where systems naturally...

10.1038/mt.2011.54 article EN cc-by-nc-nd Molecular Therapy 2011-04-12

Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim our study was to assess the immunomodulatory effect pegIFN-α on T natural killer (NK) cell responses in NUC-suppressed identify cellular and/or serological parameters predict better cell-restoring control infection response for tailored application IFN-α add-on.

10.1136/gutjnl-2024-332290 article EN Gut 2024-07-20

Monitoring antigen-specific T cell frequency and function is essential to assess the host immune response severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we present a FluoroSpot assay for concurrently detecting ex vivo antiviral cytokine production by SARS-CoV-2-specific cells following peptide stimulation. We then detail intracellular staining flow cytometry further validate results define specific subpopulations. For complete details on use execution of this...

10.1016/j.xpro.2023.102584 article EN cc-by-nc-nd STAR Protocols 2023-09-21
Coming Soon ...